Hercules, CA — February 19, 2015 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of predesigned PrimePCR™ Assays for six of the most common model organism genomes used for gene expression analysis: rhesus monkey, zebrafish, yeast, cow, rabbit, and pig.
Hercules, CA — February 19, 2015 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of predesigned PrimePCR™ Assays for six of the most common model organism genomes used for gene expression analysis: rhesus monkey, zebrafish, yeast, cow, rabbit, and pig.
Assay validation is one of the most important steps in qPCR but is sometimes overlooked because researchers may be unaware of its critical importance in generating accurate results. In addition, validating assays can be laborious and time-consuming, especially when assays do not work and need to be redesigned and reordered.
Bio-Rad’s PrimePCR Assays are fully validated in wet labs or in silico using the same algorithms and design rules. All assays are guaranteed to perform, and the raw validation data are available to customers. Researchers can use PrimePCR Assays to follow industry best practices known as MIQE (minimum information for publication of quantitative real-time PCR experiments).
The new PrimePCR Assays are available in SYBR® Green- and probe-based formats for a wide range of targets, as PreAmp assays for preamplification, and as control assays and templates. Bio-Rad also added more than 1,000 predesigned, wet-lab validated disease and pathway PrimePCR Panels for the rat genome to the existing library of 20,000 fully validated PrimePCR rat genome assays for qPCR.
For more information on Bio-Rad’s PrimePCR products, please visit www.bio-rad.com/PrimePCRpr2
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs approximately 7,800 people worldwide and had revenues exceeding $2.1 billion in 2013. For more information, visit our website at www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Kate Smith
Bio-Rad Laboratories
510-741-5307
kate_smith@bio-rad.com
Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com